PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Highlights the firm's ability to meet near-term obligations and cover interest expenses. For conservative value investors, strong liquidity and coverage metrics are critical to avoid distress or forced dilution.
1.38
Current Ratio 0.5–0.75x Drug Manufacturers - Specialty & Generic median of 2.16. Guy Spier would worry about potential short-term pinch.
1.38
Quick Ratio 0.75–0.9x Drug Manufacturers - Specialty & Generic median of 1.68. John Neff might push for better working capital control.
1.34
Cash Ratio above 1.5x Drug Manufacturers - Specialty & Generic median of 0.50. Joel Greenblatt might see a strategic advantage in crisis periods.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.